B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

308.55 -0.67 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
55 56 Next >
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
The Defensive Sectors And VIX Have NOT Given The All-Clear Signal
The market has been a rollercoaster lately, with the resilience of defensive sectors and the modest bounce in the technology sector painting an intriguing picture. 
Via Talk Markets
Topics Stocks
Amgen Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Here's Why Eli Lilly Stock Dropped 12% Last Month
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
Amgen's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $600 Today
 
Via Benzinga
Unpacking the Latest Options Trading Trends in Amgen
 
Via Benzinga
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
Amgen posted mixed Q2 results. Analysts highlight upcoming clinical readouts in obesity and inflammatory disease as crucial. Despite some underperformance, growth prospects remain strong, with... 
Via Benzinga
Why Amgen Stock Is Down Today Despite Solid Q2 Results
Shares may have been likely to fall no matter what the company reported. 
Via The Motley Fool
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?
The U.S. 
Via Benzinga
Market Whales and Their Recent Bets on AMGN Options
 
Via Benzinga
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
Amgen reported a 20% year-over-year increase in second-quarter sales, reaching $8.39 billion, surpassing the $8.33 billion consensus. Guidance for 2024 includes adjusted EPS of $19.10-$20.10 and... 
Via Benzinga
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
AMGN Stock Earnings: Amgen Misses EPS, Beats Revenue for Q2 2024
AMGN stock results show that Amgen missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Amgen Undercuts Its Buy Point On Mixed Second-Quarter Report
Amgen stock fell late Tuesday after the biotech reported lighter-than-expected second-quarter profits, though sales beat. 
Via Investor's Business Daily
Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
 
Via Benzinga
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by... 
Via Benzinga
Topics Stocks
Good Stocks, Strategic Options, and a 4.5% Yield: There's a Lot to Like About This Unique ETF
Covered calls can generate income from an investment portfolio but can be complex. This Amplify ETF is a simple solution. 
Via The Motley Fool
Topics ETFs
So Much For Expecting The Fed To Stick The Landing
Now is not the time to be fully invested. 
Via Talk Markets
Topics Economy
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday’s losses. Investors took advantage of recent volatility to buy... 
Via Benzinga
Topics Economy Stocks
3 Biotech Stocks That Could Have Investors Grinning Soon
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
Via InvestorPlace
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
The innovative biotech is looking for its next blockbuster. 
Via The Motley Fool
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
Strong sell-off may be viewed as an opportunity to load up beaten-down stocks but traders may seek evidence regarding sustainability of uptrend. 
Via Benzinga
Topics Stocks
The Top 3 Biotech Stocks to Buy Now Summer 2024
These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects. 
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Dividend-Paying ETFs to Secure Your Passive Income Stream
Passive income and ETFs represent two compelling market concepts. Why not bring the two together with dividend-paying ETFs? 
Via InvestorPlace
Topics ETFs
3 Fabulous Growth Stocks to Buy and Hold Forever
The bull market in growth stocks is more than just chipmakers if investors will only widen their lens to see the opportunities available. 
Via InvestorPlace
7 Biotech Stocks to Keep on Your Clinical Radar
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
3 Stocks That Are Melting Up. Is There Room to Run?
Buying stocks while they're melting up isn't without its fair share of risk. That said, these high-flyers look pretty enticing. 
Via InvestorPlace
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.